A Study to Test the Safety and Tolerability of Brivaracetam in Pediatric Study Participants With Seizures

  • End date
    Apr 1, 2025
  • participants needed
  • sponsor
    UCB Biopharma SRL
Updated on 1 September 2021


The purpose of the study is to evaluate the long-term safety and tolerability of brivaracetam.


EP0156 is designed to assess the long-term safety and tolerability of brivaracetam (BRV) from pediatric study participants with epilepsy who participated in the study in neonates, N01349 [NCT03325439], and/or the ongoing, open-label, long-term, follow-up study in pediatric study participants, N01266 [NCT01364597], who have the opportunity to continue BRV treatment by participating in EP0156.

EP0156 is also designed to assess the long-term safety and tolerability of BRV from directly enrolled (DE) Japanese pediatric study participants with partial-onset seizures (POS) recruited in Japan. In the DE study participants only, pharmacokinetic (PK) data will be evaluated in addition to the safety and tolerability of BRV.

Condition Epilepsy, Seizure Disorders (Pediatric), Seizure Disorders, epileptic, seizure disorder, epilepsia, epileptics
Treatment Brivaracetam
Clinical Study IdentifierNCT04715646
SponsorUCB Biopharma SRL
Last Modified on1 September 2021


Yes No Not Sure

Inclusion Criteria

Inclusion criteria for long-term follow-up (LTFU) study participants only
Study participants with a confirmed diagnosis of epilepsy who participated in core study N01266 [NCT01364597] and/or N01349 [NCT03325439] and for whom a reasonable benefit from long-term administration of brivaracetam (BRV) is expected
Inclusion criteria for directly enrolled (DE) study participants only
Study participant is 4 years to < 16 years of age
Study participant has presence of an electroencephalogram (EEG) reading compatible with the diagnosis of focal epilepsy within the last 10 years
Study participant has uncontrolled partial-onset seizure (POS) after an adequate course of treatment (in the opinion of the Investigator) with at least 1 antiepileptic drug (AED)
Study participant had at least 1 POS during the 4-week Screening Period
Study participant is taking at least 1 AED. Vagal nerve stimulator will be counted as a concomitant AED

Exclusion Criteria

Exclusion criteria for all study participants
Study participant has, in the Investigator's opinion, severe medical, neurological, or psychiatric disorders or laboratory values, which may have an impact on the safety of the study participant
Study participant has any medical condition including chronic liver disease, which in the Investigator's opinion, warrants exclusion
Study participant is currently participating in another study of an investigational medication (or a medical device) other than brivaracetam (BRV). The use of antiepileptic drugs (AEDs) marketed for adults but not approved for pediatric use is not considered to be "investigational" for the purposes of this study
Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator or medical monitor, contraindicates participation in the study
Exclusion criteria for long-term follow-up (LTFU) study participants only
Study participant had poor compliance with the visit schedule or medication intake in the BRV core study
Study participant 6 years of age has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated on the Columbia Suicide Severity Rating Scale (C-SSRS)
Exclusion criteria for directly enrolled (DE) study participants only
Study participant has a history of primary generalized epilepsy
Study participant has a history of status epilepticus in the 30 days immediately prior to the Screening Visit (ScrV) or during the Screening Period
Study participant has history or presence of known psychogenic nonepileptic seizures
Study participant has experienced febrile seizures exclusively. The occurrence of febrile seizures in addition to other unprovoked seizures is not exclusionary
Study participant has any clinically significant acute or chronic illness as determined during the physical examination or from other information available to the Investigator (eg, bone marrow suppression, chronic hepatic disease, severe renal impairment, psychiatric disorder as per Investigator assessment)
Study participant has clinically significant laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results, according to the judgment of the Investigator
Study participant has a clinically significant ECG abnormality according to the Investigator
Study participant had major surgery within 6 months prior to the ScrV
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note